相关实验视频

Updated: Jun 22, 2025

Trypsin Digest Protocol to Analyze the Retinal Vasculature of a Mouse Model

Trypsin Digest Protocol to Analyze the Retinal Vasculature of a Mouse Model

Published on: June 13, 2013

天然产品在糖尿病视网膜病变中的作用

Yuxuan Zhao^1,2, Yi Chen¹, Naihong Yan¹

¹Research Laboratory of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China.

|June 27, 2024

概括

天然产品在治疗糖尿病视网膜病变 (DR) - - 一种主要的糖尿病并发症方面表现有前途. 需要进行进一步的临床研究,以克服生物可用性和毒性等挑战,以便有效地用于管理视力丧失.

科学领域:

眼科医生眼科眼科
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

糖尿病视网膜病变 (DR) 是糖尿病的严重并发症,通常导致视力受损和失明.
由于疾病的复杂病理机制,目前对DR的治疗面临挑战.
饮食干预和天然产品 (NP) 正在成为管理DR的潜在治疗策略.

研究的目的:

探索天然产品 (NP) 在治疗糖尿病视网膜病变 (DR) 中的治疗潜力.
审查与DR相关的抗炎,抗氧化,抗神经血管和抗位作用的NP的机制和化合物.

主要方法:

对自然化合物的体外和体内研究以及它们对DR相关途径的影响的综述.
分析各种类型的天然化合物,包括沙素,,类,黄类,糖类,类和维生素.
识别阻碍NP用于DR治疗的临床应用的挑战.

主要成果:

天然化合物表现出多种有益作用,包括抗炎,抗氧化,抗血管和抗质性质.
特定的天然化合物已经在临床前模型中证明了DR病理管理的潜力.
NP的临床应用受到诸如特异性,生物可用性和潜在毒性等问题的限制.

结论:

自然产品为开发糖尿病视网膜病变的新疗法提供了一个有希望的途径.
克服与特异性,生物可用性和毒性相关的挑战对于临床翻译至关重要.
未来的临床研究对于验证NP在预防或延缓DR进展方面的治疗效果至关重要.

关键词:

糖尿病视网膜病变糖尿病视网膜病变这是一个机制机制.自然产品是自然产品的产品.毒性的毒性毒性的毒性

更多相关视频

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

Characterization of a Novel Human Organotypic Retinal Culture Technique

Characterization of a Novel Human Organotypic Retinal Culture Technique

Published on: June 9, 2021

相关概念视频

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...